CD276 and brain neoplasm: Several CAR-T-cell therapies are approved by the United States Food and Drug Administration (FDA) to treat patients suffering from hematological malignancies.14 Therapies targeting solid tumors (including brain tumors) have not yet received FDA approval and are still in the clinical trial phase.15 Despite potential complications, numerous clinical trials are currently investigating CAR-T-cell therapies targeting brain tumors through various antigens, such as EGFR, IL13Rα2, B7-H3, GD2, and CD70 (Figure 1, Table S1).